YunCheng (孕橙)

Bei Jing Shi, China

Women's Health Digital Diagnostics Home-Based Care

Yunchen focuses on the digital diagnostic platform and smart IoT industrialization in the field of home self-testing. Currently, it is targeting women's reproductive health, particularly for those facing difficulties in conceiving and those seeking optimal pregnancy outcomes. It is a leading brand in digital reproductive health in China. Since its establishment in 2013, Yunchen has been deeply engaged in the Fertility Awareness Method (FAM) medical technology and smart IoT platform. Leveraging the research capabilities of its core team from Tsinghua University and Peking University, it has combined the FAM, which originated in Germany, with real-world data from female users both domestically and internationally. This has led to the development of the iFAM algorithm, which is used by over 6 million users worldwide. The company boasts a physiological cycle database with over a billion female markers and has received professional recognition from dozens of industry users, including Beijing Obstetrics and Gynecology Hospital, Aviation General Hospital, Jinxin Reproductive, Merck China, Wanfu Biology, Mama Network, and others.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out YunCheng (孕橙) on @MedStartr Today #WomenSHealth #Infertility #Pregnancy #ReproductiveWomenSHealth #DigitalDiagnostics #HomeBasedCare #MedMo #MedStartrVentures

https://www.medstartr.ai/s/8jxwx2fyx-Y

Get Involved in YunCheng (孕橙)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2013
Website: www.shecarefertility.com/

Disease Areas

Women's Health Infertility Pregnancy Reproductive & Women's Health

Technologies

Home Health TestingWearable Devices

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of YunCheng (孕橙)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.